

ERRATUM: Table Correction

천식 환자에서 흡입용 스테로이드 장기 사용의 시상하부-뇌하수체-부신축 억제 효과

심다운, 최인선, 김승훈

전남대학교 의과대학 알레르기내과학교실

Suppressive effects of long-term treatment with inhaled steroids on hypothalamic-pituitary-adrenal axis in asthma

Da Woon Sim, Inseon S. Choi, Seung-Hun Kim

Department of Allergy, Chonnam National University Medical School, Gwangju, Korea

Allergy Asthma Respir Dis 2(4):285-292, September 2014 <http://dx.doi.org/10.4168/aard.2014.2.4.285>

Some parts of Tables 1 and 2 in this paper was described incorrectly.

The correction should be as follows (underline):

Corrected Tables 1 and 2

Table 1. The demographics and clinical characteristics of asthma patients treated with inhaled corticosteroid and classified according to the daily doses of inhaled steroids

Characteristic	Low (n=8)	Medium (n=19)	High (n=102)	P-value
Age (yr)	69.6±3.7	61.4±3.3	68.1±1.5	0.182
Female sex	3 (37.5)	8 (42.1)	47 (46.1)	0.589
Duration of ICS use (day)	1,358±230	1,856±354	1,756±127	0.651
Total ICS amount (mg)	278±64	779±158	1,467±113	0.001
Fluticasone/total ICS ratio (%)	73.8±6.8	<u>62.7±7.8</u>	81.7±2.1	<u>0.006</u>
Oral prednisolone (mg)	0	61±49	559±117	0.082
No. of nasal steroid canister	2.5±1.3	12.7±4.1	18.1±2.1	0.080
FEV ₁ (% predicted)	53.8± 9.1	66.0±6.1	50.1±2.5	0.046
Serum total IgE≥ 100 IU/mL	5 (62.5)	11 (57.9)	52 (51.0)	0.383
Morning cortisol≤ 3 µg/dL	1 (12.5)	3 (15.8)	18 (17.6)	0.690
Abnormal ACTH response*	1 (12.5)	7 (36.8)	50 (49.0)	0.036
Adrenal insufficiency†	1 (12.5)	8 (42.1)	51 (50.0)	0.052

Values are presented as mean± standard error or number (%).

ICS, inhaled corticosteroid; FEV₁, forced expiratory volume in one second; ACTH, adrenocorticotrophic hormone.

*Abnormal ACTH response: serum cortisol<18 µg/dL before and 60 minutes after administration of 250-µg adrenocorticotrophic hormone. †Adrenal insufficiency: abnormal ACTH response or morning cortisol ≤ 3 µg/dL.

Table 2. The demographics and clinical characteristics of asthma patients used inhaled corticosteroid only and classified according to the response to a 250- μ g ACTH stimulation test*

Characteristic	Normal (n=59)	Abnormal (n=28)	P-value
Age (yr)	69.8±1.8	65.6±2.8	0.202
Female sex	29 (49.2)	11 (39.3)	0.388
Duration of ICS use (day)	1,713±154	2,140±259	0.139
Total ICS amount (mg)	1,173±137	1,524±212	0.159
Fluticasone/total ICS ratio (%)	79.1±3.2	82.7±3.1	0.476
No. of nasal steroid canister	12.5±2.4	23.4±4.1	0.016
FEV ₁ (% predicted)	53.9±3.4	49.7±4.9	0.481
Serum total IgE ≥100 IU/mL (%)	30/57 (52.6)	17/28 (60.7)	0.481
Morning cortisol ≤3 μ g/dL (%)	1 (1.7)	10 (35.7)	<0.001

Values are presented as mean±standard error or number (%).

ACTH, adrenocorticotropic hormone; ICS, inhaled corticosteroid; FEV₁, forced expiratory volume in one second.

*Abnormal ACTH stimulation test: serum cortisol<18 μ g/dL before and 60 minutes after administration of 250- μ g ACTH.

이 논문 Tables 1과 2 일부에 오류가 있어 위와 같이 정정합니다.